

# Timothy M Block

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2559146/publications.pdf>

Version: 2024-02-01

57  
papers

4,516  
citations

159585

30  
h-index

149698

56  
g-index

62  
all docs

62  
docs citations

62  
times ranked

4881  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular viral oncology of hepatocellular carcinoma. <i>Oncogene</i> , 2003, 22, 5093-5107.	5.9	463
2	A global scientific strategy to cure hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 545-558.	8.1	342
3	GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2005, 43, 1007-1012.	3.7	321
4	Present and future therapies of hepatitis B: From discovery to cure. <i>Hepatology</i> , 2015, 62, 1893-1908.	7.3	269
5	Characterization of the Intracellular Deproteinized Relaxed Circular DNA of Hepatitis B Virus: an Intermediate of Covalently Closed Circular DNA Formation. <i>Journal of Virology</i> , 2007, 81, 12472-12484.	3.4	267
6	Î±-Glucosidase inhibitors as potential broad based anti-viral agents. <i>FEBS Letters</i> , 1998, 430, 17-22.	2.8	251
7	Inhibition of Hepatitis B Virus Replication by the Host Zinc Finger Antiviral Protein. <i>PLoS Pathogens</i> , 2013, 9, e1003494.	4.7	204
8	Identification of Disubstituted Sulfonamide Compounds as Specific Inhibitors of Hepatitis B Virus Covalently Closed Circular DNA Formation. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4277-4288.	3.2	194
9	Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. <i>Nature Medicine</i> , 1998, 4, 610-614.	30.7	154
10	Molecular Virology of Hepatitis B Virus for Clinicians. <i>Clinics in Liver Disease</i> , 2007, 11, 685-706.	2.1	151
11	Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes. <i>PLoS Pathogens</i> , 2013, 9, e1003613.	4.7	135
12	Glycosylation and Liver Cancer. <i>Advances in Cancer Research</i> , 2015, 126, 257-279.	5.0	128
13	Production and Function of the Cytoplasmic Deproteinized Relaxed Circular DNA of Hepadnaviruses. <i>Journal of Virology</i> , 2010, 84, 387-396.	3.4	113
14	Chronic hepatitis B: What should be the goal for new therapies?. <i>Antiviral Research</i> , 2013, 98, 27-34.	4.1	112
15	Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA. <i>PLoS Pathogens</i> , 2017, 13, e1006296.	4.7	107
16	Antiviral therapies targeting host ER alpha-glucosidases: Current status and future directions. <i>Antiviral Research</i> , 2013, 99, 251-260.	4.1	98
17	STING Agonists Induce an Innate Antiviral Immune Response against Hepatitis B Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1273-1281.	3.2	93
18	Evidence That N-Linked Glycosylation Is Necessary for Hepatitis B Virus Secretion. <i>Virology</i> , 1995, 213, 660-665.	2.4	88

#	ARTICLE	IF	CITATIONS
19	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	7.3	70
20	Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: Therapeutic implications. <i>Hepatology</i> , 2001, 33, 1488-1495.	7.3	65
21	Chronic hepatitis B: A wave of new therapies on the horizon. <i>Antiviral Research</i> , 2015, 121, 69-81.	4.1	65
22	Inhibition of Endoplasmic Reticulum-Resident Glucosidases Impairs Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 Spike Protein-Mediated Entry by Altering the Glycan Processing of Angiotensin I-Converting Enzyme 2. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 206-216.	3.2	63
23	The innate immune response to hepatitis B virus infection: Implications for pathogenesis and therapy. <i>Antiviral Research</i> , 2012, 96, 405-413.	4.1	58
24	Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B. <i>Antiviral Research</i> , 2018, 158, 185-198.	4.1	53
25	Characterization of the Host Factors Required for Hepadnavirus Covalently Closed Circular (ccc) DNA Formation. <i>PLoS ONE</i> , 2012, 7, e43270.	2.5	49
26	The Doylestown Algorithm: A Test to Improve the Performance of AFP in the Detection of Hepatocellular Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 172-179.	1.5	48
27	HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element. <i>Antiviral Research</i> , 2018, 149, 191-201.	4.1	43
28	The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: Notes from a recent workshop. <i>Cancer Biomarkers</i> , 2008, 4, 19-33.	1.7	41
29	Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. <i>Scientific Reports</i> , 2015, 5, 10478.	3.3	41
30	Data supporting updating estimates of the prevalence of chronic hepatitis B and C in the United States. <i>Hepatology</i> , 2015, 62, 1339-1341.	7.3	33
31	Differential methylation of the promoter and first exon of the <i>RASSF1A</i> gene in hepatocarcinogenesis. <i>Hepatology Research</i> , 2015, 45, 1110-1123.	3.4	31
32	Total serum glycan analysis is superior to lectin-FLISA for the early detection of hepatocellular carcinoma. <i>Proteomics - Clinical Applications</i> , 2013, 7, 690-700.	1.6	30
33	Enhancing the antiviral potency of ER $\alpha$ -glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo. <i>Antiviral Research</i> , 2018, 150, 112-122.	4.1	26
34	Prospects for the Global Elimination of Hepatitis B. <i>Annual Review of Virology</i> , 2021, 8, 437-458.	6.7	26
35	A historical perspective on the discovery and elucidation of the hepatitis B virus. <i>Antiviral Research</i> , 2016, 131, 109-123.	4.1	24
36	Imino sugar glucosidase inhibitors as broadly active anti-filovirus agents. <i>Emerging Microbes and Infections</i> , 2013, 2, 1-7.	6.5	21

#	ARTICLE	IF	CITATIONS
37	The hepatitis B epidemic and the urgent need for cure preparedness. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 517-518.	17.8	20
38	Article Commentary: Viral Resistance of MOGS-CDG Patients Implies a Broad-Spectrum Strategy against Acute Virus Infections. <i>Antiviral Therapy</i> , 2015, 20, 257-259.	1.0	19
39	Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics. <i>Clinical Infectious Diseases</i> , 2017, 64, 1283-1288.	5.8	19
40	An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses. <i>Antiviral Research</i> , 2014, 107, 56-65.	4.1	18
41	Hepatitis B Virus MHBs Antigen Is Selectively Sensitive to Glucosidase-Mediated Processing in the Endoplasmic Reticulum. <i>DNA and Cell Biology</i> , 2001, 20, 647-656.	1.9	15
42	Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care: Table 1.. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv359.	6.3	14
43	The Dihydroquinolizinone Compound RG7834 Inhibits the Polyadenylase Function of PAPD5 and PAPD7 and Accelerates the Degradation of Matured Hepatitis B Virus Surface Protein mRNA. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	14
44	Herpes simplex virus type 1 infection prevents detachment of nerve growth factor-differentiated PC12 cells in culture. <i>Journal of General Virology</i> , 2002, 83, 1591-1600.	2.9	14
45	Does Rapid Oligomerization of Hepatitis B Envelope Proteins Play a Role in Resistance to Proteasome Degradation and Enhance Chronicity?. <i>DNA and Cell Biology</i> , 2006, 25, 165-170.	1.9	13
46	Hepatoselective Dihydroquinolizinone Bis-acids for HBsAg mRNA Degradation. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1130-1136.	2.8	12
47	Synovial stimulatory protein fragments copurify with woodchuck hepatitis virus: Implications for the etiology of arthritis in chronic hepatitis B virus infection. <i>Arthritis and Rheumatism</i> , 2001, 44, 486-487.	6.7	11
48	Design and synthesis of N-alkyldeoxynojirimycin derivatives with improved metabolic stability as inhibitors of BVDV and Tacaribe virus. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 4258-4262.	2.2	10
49	Application of the Doylestown algorithm for the early detection of hepatocellular carcinoma. <i>PLoS ONE</i> , 2018, 13, e0203149.	2.5	10
50	Role of Glycan Processing in Hepatitis B Virus Envelope Protein Trafficking. <i>Advances in Experimental Medicine and Biology</i> , 1998, 435, 207-216.	1.6	10
51	Host RNA quality control as a hepatitis B antiviral target. <i>Antiviral Research</i> , 2021, 186, 104972.	4.1	7
52	Do hepatitis B virus surface antigens have any role in viral carcinogenesis?. <i>Hepatology</i> , 2018, 68, 801-803.	7.3	2
53	Abstract 4934: Detection of HBV-host junction DNA sequences in urine of patients with hepatocellular carcinoma. , 2016, , .		2
54	Surrogate markers of efficacy for medical treatment of viral hepatitis. <i>Biotechnology Healthcare</i> , 2004, 1, 42-8.	0.2	1

#	ARTICLE	IF	CITATIONS
55	Evolving New Strategies for the Medical Management of Chronic Hepatitis B Virus Infection. Gastroenterology and Hepatology, 2016, 12, 679-689.	0.1	1
56	Implications of Circulating Hepatitis B Virus RNA Levels in Assessment of Response to Antiviral Therapy. Current Hepatology Reports, 2018, 17, 451-458.	0.9	0
57	Secretion of human hepatitis B virus is inhibited by the imino sugar N-butyldeoxynojirimycin (antivirals/glycosylation). World Scientific Series in 20th Century Biology, 2000, , 552-556.	0.1	0